Holen Sie sich die Stockscreener-App
86.70
2.23%
1.89
Handel nachbörslich:
86.49
-0.21
-0.24%
Incyte Corp Aktie (INCY) Neueste Nachrichten
Poinciana Advisors Group LLC Makes New Investment in Incyte Corporation $INCY - MarketBeat
Is Incyte Corporation stock a safe buy before earnings2025 Trade Ideas & Smart Swing Trading Techniques - newser.com
Will Incyte Corporation (ICY) stock see insider accumulationQuarterly Profit Report & AI Enhanced Market Trend Forecasts - newser.com
Patton Albertson Miller Group LLC Acquires 5,497 Shares of Incyte Corporation $INCY - MarketBeat
Patton Fund Management Inc. Takes $254,000 Position in Incyte Corporation $INCY - MarketBeat
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication - GlobeNewswire Inc.
Candlestick signals on Incyte Corporation stock todayMarket Performance Recap & Breakout Confirmation Alerts - newser.com
Will Incyte Corporation stock outperform value stocks2025 EndofYear Setup & Technical Confirmation Alerts - newser.com
Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions - Yahoo Finance
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
How to use Fibonacci retracement on Incyte CorporationJuly 2025 Weekly Recap & Accurate Buy Signal Notifications - newser.com
Jim Cramer Calls Incyte “Way Too Cheap” - Yahoo Finance
Ruffer LLP Sells 9,988 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 24, 2025 - biospace.com
RBC Capital Raises Price Target for Incyte (INCY) to USD 81 | IN - GuruFocus
Incyte stock price target raised to $81 from $72 at RBC Capital - Investing.com
Guggenheim Reaffirms "Neutral" Rating for Incyte (NASDAQ:INCY) - MarketBeat
Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions - Insider Monkey
Mn Services Vermogensbeheer B.V. Sells 6,600 Shares of Incyte Corporation $INCY - MarketBeat
Is Incyte Stock Outperforming The S&P 500? - Barchart.com
Incyte Corporation (NASDAQ:INCY) Short Interest Down 21.8% in August - MarketBeat
Incyte Corporation $INCY Stake Lowered by Diversified Trust Co - MarketBeat
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer - BioSpace
NorthCrest Asset Manangement LLC Has $777,000 Stock Holdings in Incyte Corporation $INCY - MarketBeat
Sovran Advisors LLC Sells 12,174 Shares of Incyte Corporation $INCY - MarketBeat
Is Incyte Corporation a candidate for recovery playJuly 2025 Levels & Proven Capital Preservation Tips - newser.com
Incyte (NASDAQ:INCY) Price Target Raised to $115.00 at Stifel Nicolaus - MarketBeat
Stifel Raises Price Target for Incyte (INCY) to $115 While Maint - GuruFocus
Incyte appoints Dave Gardner as new chief strategy officer - Investing.com
Stifel Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛
Incyte’s SWOT analysis: stock outlook mixed amid pipeline progress, jakafi concerns - Investing.com
Incyte stock price target raised to $115 by Stifel on pediatric approval - Investing.com
Incyte (NASDAQ:INCY) EVP Sells $23,115.70 in Stock - MarketBeat
Pallas Capital Advisors LLC Reduces Holdings in Incyte Corporation $INCY - MarketBeat
Perpetual Ltd Purchases New Holdings in Incyte Corporation $INCY - MarketBeat
34,082 Shares in Incyte Corporation $INCY Acquired by Strs Ohio - MarketBeat
How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA Approval - Yahoo Finance
Swedbank AB Raises Stock Holdings in Incyte Corporation $INCY - MarketBeat
Baader Bank Aktiengesellschaft Invests $424,000 in Incyte Corporation $INCY - MarketBeat
4,558 Shares in Incyte Corporation $INCY Purchased by OMNI 360 Wealth Inc. - MarketBeat
Incyte Corporation (NASDAQ:INCY) Given Average Rating of "Hold" by Brokerages - MarketBeat
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN
Guggenheim Reiterates Neutral Rating for Incyte (INCY) | INCY Stock News - GuruFocus
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - Yahoo Finance
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In ChildrenIncyte (NASDAQ:INCY) - Benzinga
Incyte (NASDAQ:INCY) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Invst LLC Makes New $315,000 Investment in Incyte Corporation $INCY - MarketBeat
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) - Benzinga
CEO Change: Is Incyte Corporation showing insider buyingMarket Activity Summary & Advanced Technical Signal Analysis - خودرو بانک
Loss Report: What is the next catalyst for Incyte CorporationJuly 2025 Decliners & Target Return Focused Stock Picks - خودرو بانک
FDA approves Opzelura for atopic dermatitis in children ages 2 and up - Investing.com
US FDA approves Incyte's eczema cream for pediatric patients - Reuters
FDA Greenlights Incyte's Opzelura Cream for Pediatric Dermatitis Treatment - GuruFocus
FDA Approves Incyte's (INCY) Opzelura Cream for Pediatric Dermatitis - GuruFocus
Incyte gets FDA nod for Opzelura cream in atopic dermatitis treatment - Seeking Alpha
2.95%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):